COVID-19 Vaccines and Therapeutics

Since the start of the COVID-19 pandemic, a remarkable research and innovation effort has gone into combating the SARS-CoV-2 virus and COVID-19 disease. In response, WIPO published two patent landscape reports on COVID-19 vaccines and therapeutics.

The first report, "COVID-19-related vaccines and therapeutics, preliminary insights on related patenting activity during the pandemic" analyzed related patent filings from the beginning of 2020 through September 2021, providing early observations on patenting activity in the field of COVID-19 vaccines and therapeutics.

The second report, "COVID-19 Vaccines and Therapeutics, insights into related patenting activity throughout the pandemic", examined related patent filings from January 2020 through September 2022, providing a comprehensive review of patenting activity and building on insights from the first WIPO COVID-19 Patent Landscape Report.

Watch our launch event where we have invited experts from WHO, WTO, MPP, WIPO, and CAS to discuss recent developments in technologies related to various vaccine platforms and therapeutics targeting COVID-19, as well as partnerships and collaborations in research and development (R&D).

Featured
patent-landscape-report-cover
Image: WIPO

Patent Landscape Report - COVID 19 Vaccines and Therapeutics, insights into related patenting activity throughout the pandemic

This report provides observations on COVID-19 vaccines and therapeutics based on a comprehensive review of related patent filings from Jan 2020 to Sep 2022, building on insights from the first WIPO COVID-19 Patent Landscape Report.

Previous edition

patent-landscape-report-cover

Patent Landscape Report

COVID-19-related vaccines and therapeutics, preliminary insights on related patenting activity during the pandemic

This report analyzed related patent filings from the beginning of 2020 through September 2021. It provides early observations on the patenting activity which took place in the field of COVID-19 vaccines and therapeutics, and compares these results with clinical trial data for related candidate vaccines and drugs.

|